Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$5.42
-0.5%
$5.42
$4.41
$8.69
$2.03B0.421.91 million shs1.04 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$698.25
-2.1%
$744.69
$476.49
$821.11
$73.82B0.3809,342 shs728,000 shs
Snap Inc. stock logo
SNAP
Snap
$5.53
+3.1%
$5.19
$3.81
$10.41
$9.34B1.0547.50 million shs37.90 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
0.00%-6.11%-6.76%-9.54%+18.64%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-2.33%-6.40%-13.06%+22.21%
Snap Inc. stock logo
SNAP
Snap
0.00%-9.19%-8.45%+14.04%-38.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$5.42
-0.5%
$5.42
$4.41
$8.69
$2.03B0.421.91 million shs1.04 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$698.25
-2.1%
$744.69
$476.49
$821.11
$73.82B0.3809,342 shs728,000 shs
Snap Inc. stock logo
SNAP
Snap
$5.53
+3.1%
$5.19
$3.81
$10.41
$9.34B1.0547.50 million shs37.90 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
0.00%-6.11%-6.76%-9.54%+18.64%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%-2.33%-6.40%-13.06%+22.21%
Snap Inc. stock logo
SNAP
Snap
0.00%-9.19%-8.45%+14.04%-38.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.80
Reduce$8.0047.55% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.77
Moderate Buy$826.5918.38% Upside
Snap Inc. stock logo
SNAP
Snap
2.29
Hold$7.9143.09% Upside

Current Analyst Ratings Breakdown

Latest REGN, SNAP, and BHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Snap Inc. stock logo
SNAP
Snap
DowngradeStrong-BuyHold
5/7/2026
Snap Inc. stock logo
SNAP
Snap
Lower Price TargetNeutral$8.00 ➝ $7.00
5/7/2026
Snap Inc. stock logo
SNAP
Snap
Set Price Target$8.00
5/7/2026
Snap Inc. stock logo
SNAP
Snap
Lower Price TargetUnderweight$7.00 ➝ $6.00
5/7/2026
Snap Inc. stock logo
SNAP
Snap
Lower Price TargetSector Perform$10.00 ➝ $8.00
5/7/2026
Snap Inc. stock logo
SNAP
Snap
Boost Price TargetEqual Weight$6.00 ➝ $7.00
5/4/2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
DowngradeSell (D)Sell (D-)
5/1/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Boost Price TargetBuy$975.00 ➝ $995.00
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetSector Perform$779.00 ➝ $762.00
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetOverweight$923.00 ➝ $917.00
4/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Lower Price TargetBuy$801.00 ➝ $796.00
(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$10.53B0.19$7.33 per share0.74($2.89) per share-1.88
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.15$41.99 per share16.63$297.23 per share2.35
Snap Inc. stock logo
SNAP
Snap
$6.10B1.53N/AN/A$1.23 per share4.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$157M-$3.24N/A1.42N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$41.0417.0116.821.5529.65%13.16%10.17%7/30/2026 (Estimated)
Snap Inc. stock logo
SNAP
Snap
-$460.49M-$0.24N/A69.06N/A-6.72%-18.92%-5.44%8/4/2026 (Estimated)

Latest REGN, SNAP, and BHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Snap Inc. stock logo
SNAP
Snap
$0.09-$0.05-$0.14-$0.05$1.53 billion$1.53 billion
4/29/2026Q1 2026
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion
4/29/2026Q1 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billion
2/18/2026Q4 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$1.21$1.08-$0.13-$0.30$2.71 billion$2.78 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.54%N/A9.16%N/A
Snap Inc. stock logo
SNAP
Snap
N/AN/AN/AN/AN/A

Latest REGN, SNAP, and BHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.55%5/20/20265/20/20266/4/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
54.68
1.32
0.97
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.57
2.96
Snap Inc. stock logo
SNAP
Snap
1.67
3.53
3.56

Institutional Ownership

CompanyInstitutional Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
78.65%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Snap Inc. stock logo
SNAP
Snap
47.52%

Insider Ownership

CompanyInsider Ownership
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20.67%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
Snap Inc. stock logo
SNAP
Snap
22.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,300373.81 million296.55 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410105.72 million98.35 millionOptionable
Snap Inc. stock logo
SNAP
Snap
5,2611.69 billion1.31 billionOptionable

Recent News About These Companies

Snap: Cost Cuts Won't Help If Developed Markets Users Leave
Snap (NYSE:SNAP) Trading Up 4.8% - Time to Buy?
Snap (NYSE:SNAP) Trading Up 4.8% - Here's Why
Snap (NYSE:SNAP) Cut to "Hold" at Freedom Capital
HRSoft (OTCMKTS:WSTM) & Snap (NYSE:SNAP) Critical Comparison
Snap (NYSE:SNAP) Price Target Raised to $7.00
Snap (NYSE:SNAP) Upgraded to "Buy" at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$5.42 -0.03 (-0.51%)
Closing price 05/15/2026 03:59 PM Eastern
Extended Trading
$5.48 +0.05 (+0.98%)
As of 05/15/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$698.25 -14.62 (-2.05%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$698.33 +0.08 (+0.01%)
As of 05/15/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Snap stock logo

Snap NYSE:SNAP

$5.52 +0.17 (+3.08%)
Closing price 05/15/2026 03:59 PM Eastern
Extended Trading
$5.50 -0.03 (-0.45%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, collection ads, dynamic ads, story ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.